| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA511: Brodalumab for treating moderate to severe plaque psoriasis |
|
Medicine details |
|
| Medicine name | brodalumab (Kyntheum®) |
| Formulation | 210 mg solution for injection |
| Reference number | 1505 |
| Indication | Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy |
| Company | LEO Pharma |
| BNF chapter | Skin |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 28/03/2017 |
| NICE guidance | TA511: Brodalumab for treating moderate to severe plaque psoriasis |